Depressive Disorder Clinical Trial
Official title:
Dehydroepiandrosterone Treatment of Mid-Life-Related Mood Disorders in Women and Men
Dehydroepiandrosterone (DHEA) is a hormone produced by the adrenal gland. As humans grow
older the levels of DHEA naturally decrease. Low levels of DHEA have been associated with a
variety of harmful effects, including increased heart disease, decreased immune system
function, decreased bone density (osteoporosis), high cholesterol, and increased fat to
muscle ratio.
Blood levels of DHEA and its sulfate form, DHEA-S, begin dropping when humans are in their
20's. By the time humans are in their 40's and 50's, levels of DHEA and DHEA-S levels are at
50% of their peak. Previous studies have shown that levels of these hormones are associated
with feelings of "well-being" and enjoyment of "leisure" activities.
In this study researchers are interested in the effects on mood and behavior of DHEA in men
and women with mid-life related mood disorders. Specifically, researchers would like to find
out if increasing levels of DHEA will lessen the symptoms associated with these disorders.
Dehydroepiandrosterone (DHEA) is a hormone produced by the adrenal gland in concentrations
that decrease with age. In humans low DHEA levels have been associated with a variety of
adverse biological consequences, including increased cardiovascular disease, decreased
immune function, decreased bone density, negative lipid profile and an increased fat to
muscle ratio.
In this study, we investigate the effects on mood and behavior of DHEA in men and women with
midlife-related mood disorders in a double-blind, placebo-controlled, crossover trial. We
specifically ask whether increasing DHEA levels will mitigate any or all of the
neurasthenia-like symptoms characteristic of these disorders.
;
Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01316926 -
Paxil CR Bioequivalence Study Brazil
|
Phase 1 | |
Recruiting |
NCT06187454 -
Transcranial Direct Current Stimulation for Depression
|
N/A | |
Completed |
NCT04469322 -
Pharmacogenetic Implementation Trial in Veterans With Treatment Refractory Depression
|
N/A | |
Recruiting |
NCT05768126 -
Prediction of ECT Treatment Response and Reduction of Cognitive Side-effects Using EEG and Rivastigmine
|
Phase 4 | |
Completed |
NCT03219879 -
Telephone-administered Relapse Prevention for Depression
|
N/A | |
Recruiting |
NCT06038721 -
Unified Protocol: Community Connections
|
N/A | |
Completed |
NCT03043560 -
Study to Treat Major Depressive Disorder With a New Medication
|
Phase 2 | |
Completed |
NCT04091139 -
Research of Unified Protocol for the Treatment of Common Mental Disorders in Adolescents in Hong Kong
|
Phase 2/Phase 3 | |
Completed |
NCT00069459 -
Seasonal Affective Depression (SAD) Study
|
Phase 1 | |
Recruiting |
NCT05503966 -
Combining Antidepressants and Attention Bias Modification in Depression
|
N/A | |
Recruiting |
NCT03001245 -
Interpersonal Counseling (IPC) for Treatment of Depression in Adolescents
|
N/A | |
Completed |
NCT02939560 -
TMS for Adults With Autism and Depression
|
N/A | |
Completed |
NCT02452892 -
Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)
|
N/A | |
Completed |
NCT02542891 -
European Comparative Effectiveness Research on Internet-based Depression Treatment
|
N/A | |
Withdrawn |
NCT02238730 -
Ultrabrief Right Unilateral and Brief Pulse Bitemporal Electroconvulsive Therapy
|
N/A | |
Completed |
NCT02306551 -
Well Being And Resilience: Mechanisms of Transmission of Health and Risk
|
||
Completed |
NCT02224508 -
Evaluation of a Health Plan Initiative to Mitigate Chronic Opioid Therapy Risks
|
N/A | |
Completed |
NCT01407575 -
Buprenorphine for Treatment Resistant Depression
|
Phase 3 | |
Completed |
NCT01597661 -
Bupropion & Cardio Birth Defect (Slone)
|
N/A | |
Completed |
NCT01093053 -
Mind-Body Skills Groups for the Treatment of War Zone Stress in Military and Veteran Populations
|
N/A |